Lucas Decuypere

CEO

Allegro (Antwerp, Belgium) is changing the trajectory of chronic joint disease, introducing the first disease-modifying injectable, combined with real-time diagnostics, and precision delivery to redefine how osteoarthritis and related conditions are treated.

Therapeutic: Orthopedics-Spine; Osteo Arthritis

Michael Mrochen

Co-Founder

Presbyopia affects over 2 billion people and remains insufficiently addressed. We have introduced a tissue-based corneal solution, already commercially launched in Europe and Canada with growing surgeon adoption and repeat sales. In parallel, we secured FDA IDE approval for our U.S. feasibility study, positioning us for structured expansion into North America. This is a company moving from validation to scale—commercial revenues today, regulatory milestones ahead, and a clear pathway to strategic value creation.

Therapeutic: Biomaterials; Tissue technology

David Neale

CEO

Cardiac Ablation. Coherent Sine Burst Electroporation, the next Generation Pulsed Field Ablation fro treatment of Atrial Fibrillation and other arrhythmias.

Therapeutic: Cardiovascular

Eric Meeder

CEO

SyCap from Avalanche Medical (Maastricht, Netherlands) is a groundbreaking solution for middle-aged patients (35–65 years old) suffering from focal cartilage defects. It bridges the treatment gap between cartilage repair and total knee replacement (TKR), offering a joint preservation approach. It improves quality of life by addressing debilitating symptoms of cartilage defects. The implant is designed to postpone the need for total knee replacement and to delay the onset of Osteoarthritis. We have a 1,4B market opportunity and potential line expansion.

Therapeutic: Orthopedics-Spine; Focal Cartilage defect

Sarah van Hellenberg Hubar-Fisher

CEO

Bioretec’s (Finland) breakthrough technologies — RemeOs™, the first osteopromotive absorbable metal implant, and Activa, the first self-reinforced polymer implant — define a new standard of care: two absorbable technologies, one goal — healing beyond absorption.

Therapeutic: Orthopedics-Spine

Chloe Brown

CEO

Coming soon.

Therapeutic: Coming soon.

Frank Desiere

CEO

CorTec (Freiburg, Germany) provides the Brain Interchange (BIC), a fully implantable, wireless, 32-channel closed-loop brain-computer interface capable of simultaneous neural sensing and electrical stimulation. The system utilises flexible ECoG surface electrodes to interact with neural networks at the cortical level, avoiding the tissue damage associated with penetrating microelectrodes. It is currently in human clinical trials for stroke rehabilitation, addressing a multi-billion dollar therapeutic market that includes neurorehabilitation, depression, and other psychiatric disorders.

Therapeutic: Neuromodulation-Neurostimulation; Brain-Computer Interfaces

Joe Landolina

CEO & Co-founder

Cresilon (Brooklyn, New York, United States) develops advanced solutions that deliver rapid bleeding control for when seconds matter™. Cresilon’s proprietary hemostatic gel technology is made from a plant-based biopolymer that stops bleeding on contact. The platform technology is the first and only ready-to-use flowable hemostatic gel effective for all bleed types and severities, from trauma care to biosurgery. Cresilon has two commercialized products: TRAUMAGEL and VETIGEL – which have been used to save thousands of lives. The technology was named a 2025 TIME Magazine Best Invention.

Therapeutic: Wound management; Surgery

Patrick Killoran

Managing Director/CSO

Founded at the University of Cambridge’s Darwin Building, Depletura Ltd (Ely, Cambridgeshire, UK) is advancing bleeding management through novel collagen-based haemostatic technology. Integrating academic research with frontline clinical insight, and backed by a leading professor of trauma surgery, the company develops scalable, next-generation solutions for emergency, surgical, and trauma care. The Clotta™ (human) and ClottaVet™ (veterinary) platform delivers rapid, reliable bleed control designed for real-world clinical performance and commercial deployment.

Therapeutic: Bleed control, trauma medicine, surgery

Kei Mueller

CEO & Co-founder

Digital Twins Guiding Pulmonary Care. From Munich/Bavaria, Germany.

Therapeutic: Artificial Intelligence; Respiratory, Health Tech

Maurits Huigen

CEO

Coming soon.

Therapeutic: Coming soon.

Martin Stauber

CEO & Founder

GratXray (Schlieren, Zurich, Switzerland) is an innovative medical technology company dedicated to transforming diagnostic imaging. As a spin-off from Paul Scherrer Institute and ETH Zurich, we combine world-class research with practical innovation to address real clinical needs. Our first product, senoa, revolutionizes breast cancer diagnosis with pain-free, high-precision 3D imaging. By eliminating the compression required in traditional mammography and prioritizing patient comfort, we're making life-saving breast imaging more accessible, especially for women who have avoided screening due to discomfort or fear.

Therapeutic: Imaging; Breast cancer imaging

Arash Dodge

CEO

Coming soon.

Therapeutic: Coming soon.

Sophie Brac de la Perrière

CEO & co-founder

Healshape (Lyon, France) is a regenerative medicine company aiming company aiming to empower patients to regenerate themselves. Our first product is a 100% natural and resorbable bioprosthesis for women who have undergone a mastectomy following breast cancer. This soft, biosourced, 3D printed scaffold promotes natural tissue regeneration in the patient before being absorbed.

Therapeutic: Oncology; Women's Health

Thomas Bancel

CEO

Endobronchial ablation with real-time control.

Therapeutic: Minimally invasive surgery; Interventional / Respiratory

Corentin Gondrand

CEO

For transplant patients, waiting days for blood test results can mean the difference between timely treatment and dangerous complications. Under the direction of Co-Founder and CEO Corentin Gondrand, QuantiLight (Heidelberg, Baden-Wurttemberg, Germany) is eliminating that wait, delivering lab-grade results in just 15 minutes, right at the point of care. Fueled by bioluminescent sensor technology from the Max Planck Institute for Medical Research, the Heidelberg-based startup is addressing delays in therapeutic drug monitoring (TDM) that affect millions of patients worldwide. Backed by clinical proof-of-concept and advancing toward CE-IVD and FDA submissions, QuantiLight is on track to transform diagnostic workflows for transplant patients and beyond.

Therapeutic Category: Diagnostics

Andrew Grace

CEO

Coming soon.

Therapeutic: Coming soon.